By Dr Subotheni Thavaneswaran

Conference Abstracts

Gaughran G; Caillet V; Harris SJ; Thavaneswaran S; Ballinger ML; Zong J; Said Q; Bernard-Gauthier V; Kee D; Napier CE; Zaheed M; Papadopoulos L; Yap M; Simes J; Thomas DM, 2026, 'HER2 mutations in advanced NSCLC: Prevalence, mutational context, and clinical outcomes from an Australian clinico-genomic database.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 44, pp. e20673 - e20673, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 29 May 2026 - 02 June 2026, http://dx.doi.org/10.1200/JCO.2026.44.16_suppl.e20673

Yuile A; Satgunaseelan L; Alexander KL; Thavaneswaran S; Sim H-W; Zaman A; Powell J; Meng A; Escher C; Wei JQ; Wei G; Lee M; Buckland ME; Kong BY; Kastelan M; Wong M; Wilson I; Bayly A; Varikatt W; Lwin Z; Rodriguez M; Soh HC; Gill A; Zakarya R; Back MF; Pavlakis N; Chan DL; Lee A; Wheeler HR; Hudson AL, 2025, 'PATH-18. Investigating the role of CDKN2A loss in IDH-mutant gliomas: biological insights beyond tumour grading', in Neuro-Oncology, Oxford University Press (OUP), Vol. 27, pp. v243 - v244, http://dx.doi.org/10.1093/neuonc/noaf201.0970

Southi N; Sim H-W; Grady J; Satgunaseelan L; Huang M; Kansara M; Yuile A; Zaman A; Lin F; Wheeler H; Hudson A; Ballinger ML; Thomas DM; Thavaneswaran S, 2025, 'PATH-52. Understanding the prevalence ofMTAP andCDKN2A/B deletion in gliomas by next generation sequencing', in Neuro-Oncology, Oxford University Press (OUP), Vol. 27, pp. v252 - v252, http://dx.doi.org/10.1093/neuonc/noaf201.1004

Thavaneswaran S; Koh E-S; Sim H-W; Ballinger ML; Thomas DM; Barnes EH; Kong B; O’Callaghan C; Pitz M; Hawkins C; Roberge D; Pallimulla S; Ralston L; Yip S; Day BW; Verhaak RGW; Buckland M; Amanuel B; Simes J; De Lourenco RA; Solano NZ; Calder R; Adda L; Ahern E; Cooper A; Dowling A; Harrup R; Kichenadasse G; Lau B; Lynam J; Lwin Z; Wheeler H; Whittle JR; Norrie A; Harrison R; Mason WP; de Robles P; Maddula M; Gan HK, 2025, 'TIP-16. Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS (LUMOS2) study', in Neuro-Oncology, Oxford University Press (OUP), Vol. 27, pp. v423 - v424, http://dx.doi.org/10.1093/neuonc/noaf201.1676

Thavaneswaran S; Espinoza D; Lin FP; Chinchen S; Kansara M; Ballinger M; Grady J; Grimison P; Millward M; Ladwa R; Joshua AM; Desai J; Simes J; Thomas D, 2025, '973P Phase II trial of Vismodegib in advanced cancers with Hedgehog pathway alterations', in Annals of Oncology, Elsevier, Vol. 36, pp. s637, http://dx.doi.org/10.1016/j.annonc.2025.08.1542

Lin FP; Mersiades A; Lee J; Xu W; Chinchen S; Charakidis M; Thavaneswaran S; Hughes BGM; Underhill CR; Takhar HS; Harrup R; Nagrial A; Millward M; Desai J; Espinoza D; Lee CK; Solomon BJ; Simes J; Pavlakis N; Thomas D, 2024, '623P Phase II trial of vemurafenib (VEM) and cobimetinib (COB) in BRAF V600-mutated solid tumours and first-line (1L) non-small cell lung cancer (NSCLC): Australian molecular screening and therapeutics (MoST) substudy 12', in Annals of Oncology, Elsevier, SPAIN, Barcelona, Vol. 35, pp. s498, presented at Annual Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 13 September 2024 - 17 September 2024, http://dx.doi.org/10.1016/j.annonc.2024.08.690

Lin FPY; Grady JP; Napier CE; Callow M; Thavaneswaran S; Huang ML; Zaheed M; Kansara M; Sebastian L; Ballinger ML; Simes J; Thomas DM, 2024, 'Impact of artificial intelligence (AI) decision support on clinical trial participation: A before-after implementation study on a nationwide molecular tumor board.', in Journal of Clinical Oncology, Vol. 42, pp. 1557 - 1557, http://dx.doi.org/10.1200/JCO.2024.42.16_suppl.1557

Kong BY; Lin FP-Y; Espinoza D; Thavaneswaran S; Meniawy T; Desai J; Harrup R; Selva-Nayagam S; Charakidis M; Cuff K; Sebastian L; Lee CK; Chinchen S; Thomas DM; Ballinger ML; Simes J; Goldstein D, 2024, '636P Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudy', in Annals of Oncology, Elsevier, Vol. 35, pp. s505, http://dx.doi.org/10.1016/j.annonc.2024.08.703

Serie D; Pickering C; Rice R; Wong M; Huang H; Kansara M; Thavaneswaran S; Ballinger ML; Sebastian L; Thomas DM; Lindpaintner K, 2022, 'Serum glycoproteomic signatures and association with survival in patients with bone and soft tissue sarcoma treated with immune-checkpoint inhibitor therapy.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022

Lin FP-Y; Thavaneswaran S; Grady JP; Napier CE; Kansara M; Sebastian L; Kee D; Oakes SR; Blackburn J; Scott HS; Glover A; Fox SB; Goldstein D; Leo P; Amanuel B; Desai J; Lee CK; Ballinger ML; Simes J; Thomas DM, 2022, 'Molecular therapy selection in treatment-refractory advanced cancers: A retrospective cohort study determining the utility of TOPOGRAPH knowledge base.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 3073 - 3073, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.3073

Serie D; Pickering C; Rice R; Wong M; Huang H; Kansara M; Thavaneswaran S; Ballinger ML; Sebastian L; Thomas DM; Lindpaintner K, 2022, 'Serum glycoproteomic signatures and association with survival in patients with bone and soft tissue sarcoma treated with immune-checkpoint inhibitor therapy.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 11546 - 11546, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.11546

Thavaneswaran S; Ballinger ML; Grady J; Cowley M; Joshua A; Sebastian L; Collignon E; Silvestri A; Kansara M; Pinese M; Sjoquist KM; Hague W; Lee CK; Simes J; Thomas DM, 2019, 'The Cancer Molecular Screening and Therapeutics Program (MoST): Actionable mutation frequencies in a population with rare and less common cancers.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 37, pp. 3136 - 3136, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.3136

Thavaneswaran S; Sebastian L; Ballinger M; Cowley M; Grady J; Joshua A; Lee C; Sjoquist K; Hague W; Simes J; Thomas D, 2018, 'The cancer molecular screening and therapeutics program (MoST): A molecular screening platform with multiple, parallel, signal-seeking therapeutic substudies', in Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii147, http://dx.doi.org/10.1093/annonc/mdy279.434

Back to profile page